莫加莫珠单抗治疗成人T细胞白血病/淋巴瘤患者期间的腹水潴留
Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
作者信息
Shima Takahiro, Kamezaki Kenjiro, Higashioka Kazuhiko, Takashima Shuichiro, Yoshimoto Goichi, Kato Koji, Muta Tsuyoshi, Takenaka Katsuto, Iwasaki Hiromi, Miyamoto Toshihiro, Akashi Koichi
机构信息
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan.
出版信息
Intern Med. 2016;55(13):1793-6. doi: 10.2169/internalmedicine.55.5987. Epub 2016 Jul 1.
A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.
一名74岁患有难治性成人T细胞白血病/淋巴瘤（ATLL）的女性接受了三个疗程的莫加莫拉单抗治疗。尽管实现了完全缓解，但她随后出现了进行性腹水。对腹水的分析和实验室检查未发现ATLL侵袭、传染病或肝硬化的证据。莫加莫拉单抗在腹水中的浓度维持在血浆浓度的约10-15%。莫加莫拉单抗被认为是她腹水可能的发病机制。据我们所知，这是首例提示莫加莫拉单抗诱导腹水的报告。
Zotero 插件